IQVIA HoldingsIQV

About IQVIA Holdings

IQVIA Holdings is a contract research organization and health-data business serving pharmaceutical, biotechnology, and medical-device customers worldwide. It reports through three segments: Research & Development Solutions, which runs clinical trials from Phase I through Phase IV on behalf of drug developers; Technology & Analytics Solutions, which licenses proprietary datasets on prescriptions, patient claims, and physician activity together with analytics software; and Contract Sales & Medical Solutions, a smaller unit providing outsourced field sales and medical affairs teams. Research & Development Solutions generates the majority of revenue, but the data and analytics franchise carries structurally higher margins and typically contributes a disproportionate share of segment profit relative to its top-line weight.

Serious holders track backlog conversion and book-to-bill in the R&D Solutions business, since the trial pipeline underwrites revenue for years forward but is exposed to biotech funding cycles, sponsor cancellations, and delays at the U.S. Food and Drug Administration and European Medicines Agency. Customer concentration among large pharmaceutical sponsors, exposure to emerging-biotech budgets tied to capital-markets conditions, and foreign-currency translation from a large ex-U.S. footprint are recurring themes. Regulatory scrutiny of patient-data monetization, particularly under HIPAA in the United States and GDPR in Europe, is a durable overhang. Capital allocation has skewed heavily toward share repurchases funded partly by debt, keeping leverage a governance discussion.

The modern company traces to Quintiles Transnational, founded in 1982 in North Carolina by biostatistician Dennis Gillings, and to IMS Health, which grew out of pharmaceutical market-research work dating to the 1950s and was itself taken private and re-listed multiple times. Quintiles and IMS combined in a 2016 merger of equals and rebranded as IQVIA in 2017, marrying trial-operations scale with proprietary healthcare data assets. The parent, IQVIA Holdings Inc., is incorporated in Delaware and headquartered in Durham, North Carolina, with additional operating hubs in Danbury and around the world. It trades on the New York Stock Exchange and is a component of the S&P 500.

Revenue accrues under multi-year service contracts with drug and device sponsors for trial design, patient recruitment, site management, and biostatistical work, alongside subscription and transactional licenses for data assets and software-as-a-service analytics. Trial contracts are typically fixed-fee or unit-based with pass-through costs, converting from backlog into revenue as milestones are reached, while data offerings renew annually with embedded price escalators. Competitive position rests on the scale of its global trial network, longitudinal patient datasets that are difficult to replicate, and integrated technology such as the Orchestrated Clinical Trials platform. Principal rivals include Labcorp's clinical development arm, ICON, Parexel, Syneos Health, and Thermo Fisher's PPD unit; the Americas contribute the plurality of revenue, with Europe, the Middle East and Africa and Asia-Pacific rounding out the geographic mix.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full SEC-based report on IQVIA Holdings →